OMER Omeros Corporation

16.63
0  0%
Previous Close 16.63
Open
Price To Book -6.73
Market Cap 815,832,312
Shares 49,057,866
Volume 0
Short Ratio
Av. Daily Volume 387,079

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial initiation announced January 2, 2018.
OMS721
Hematopoietic stem cell-associated TMA (HSCT-TMA)
Phase 3 trial enrollment initiated February 2018. Phase 2 data released October 1, 2018 showed only marginal improvement compared with placebo.
OMS721
IgA nephropathy
Phase 2 data released October 2016.
OMS721
Kidney disorders
Approved June 2, 2014.
Omidria
Cataract surgery
Phase 3 enrollment has opened - noted March 16, 2017.
OMS721
Atypical hemolytic uremic syndrome (aHUS)
Phase 1 trial to be completed 3Q 2019.
OMS527
Nicotine Addiction

Latest News

  1. Edited Transcript of OMER earnings conference call or presentation 9-May-19 8:30pm GMT
  2. Omeros Corporation Announces Assignment of Rapporteurs for European Marketing Authorization Application for Narsoplimab for Treatment of HSCT-TMA
  3. Is Omeros Corporation's (NASDAQ:OMER) CEO Paid At A Competitive Rate?
  4. Omeros to Present at the UBS Global Healthcare Conference
  5. Omeros (OMER) Q1 2019 Earnings Call Transcript
  6. Omeros (OMER) Reports Q1 Loss, Lags Revenue Estimates
  7. Omeros: 1Q Earnings Snapshot
  8. Omeros Corporation Reports First Quarter 2019 Financial Results
  9. Did Hedge Funds Drop The Ball On Omeros Corporation (OMER) ?
  10. Clinical Study Showing Reduced Incidence of Cystoid Macular Edema with OMIDRIA® Presented at American Society of Cataract and Refractive Surgery Annual Meeting
  11. Omeros Corporation to Announce First Quarter 2019 Financial Results on May 9, 2019
  12. Will Omeros (OMER) Report Negative Q1 Earnings? What You Should Know
  13. Omeros Corporation Announces Presentation of OMIDRIA® Real-World Data at Upcoming American Society of Cataract and Refractive Surgery Annual Meeting
  14. Omeros Corporation Announces EBMT Case Report of Resolution of Gastrointestinal Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Following Narsoplimab Treatment
  15. Omeros Corporation Announces Upcoming Educational Event at the Annual Meeting of the European Society of Blood and Marrow Transplantation
  16. What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?
  17. Edited Transcript of OMER earnings conference call or presentation 1-Mar-19 1:30pm GMT
  18. Omeros Corporation Reports Fourth Quarter and Year-End 2018 Financial Results
  19. Omeros Corporation to Announce Fourth Quarter and Year-End 2018 Financial Results on March 1, 2019
  20. Investor Expectations to Drive Momentum within Graphic Packaging Holding, Vulcan Materials, Omeros, Koppers, uniQure N.V, and WAVE Life Sciences — Discovering Underlying Factors of Influence